肝动脉化疗栓塞联合阿帕替尼治疗中晚期肝癌的效果和安全性

• 作 者: 郑爱枝 王光霞 张毓珍
• 机 构: 郑州大学第一附属医院感染性疾病科 450052
• 出 处: 中国实用医刊
• 发表日期: 2022年2期
• 关键词: Apatinib Hepatic artery chemoembolization Liver cancer

目的:探讨肝动脉化疗栓塞(TACE)联合阿帕替尼治疗中晚期肝癌的效果和安全性。方法:抽取2019年6月至2020年6月郑州大学第一附属医院收治的中晚期肝癌患者120例作为研究对象，按随机数字表法分为对照组和观察组，每组60例。对照组采用TACE治疗，观察组在对照组基础上联合阿帕替尼治疗。治疗3个月后，比较两组的治疗效果、血清肿瘤标志物包括血管内皮细胞生长因子(VEGF)、基质金属蛋白酶-9(MMP-9)、半胱氨酰天冬氨酸蛋白酶8(Caspase-8)、甲胎蛋白(AFP)水平及不良反应发生率。结果:观察组治疗有效率(61.67%)优于对照组(43.33%)、疾病控制率(83.33%)优于对照组(63.33%)，差异均有统计学意义(n P均0.05)，治疗后，两组血清VEGF、MMP-9、AFP水平均下降，Caspase-8水平升高，且观察组血清VEGF、MMP-9、AFP水平低于对照组，Caspase-8水平高于对照组，差异均有统计学意义(n P均0.05)，但观察组的皮疹、高血压、蛋白尿发生率均高于对照组(n P均<0.05)。n 结论:阿帕替尼联合肝动脉化疗栓塞治疗中晚期肝癌能够有效提高治疗效果、控制肿瘤发展进程，但同时也会增加不良反应发生率，需谨慎使用。“,”Objective:To investigate the clinical effect and safety of transcatheter arterial chemoembolization (TACE) combined with apatinib in the treatment of advanced liver cancer.Methods:A total of 120 patients with advanced liver cancer admitted to the First Affiliated Hospital of Zhengzhou University from June 2019 to June 2020 were selected as the study subjects, and they were divided into control group and observation group according to random number table method, with 60 cases in each group.The control group was treated with TACE, and the observation group was treated with apatinib on the basis of the control group. After 3 months of treatment, the efficacy, tumor markers including vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), cysteine aspartic acid specific protease (Caspase-8), alpha fetoprotein (AFP) levels in serum and the incidence of adverse reactions were compared between the two groups.Results:The effective rate of the observation group (61.67%) was better than that of the control group (43.33%), and the disease control rate (83.33%) was better than that of the control group (63.33%), the differences were all statistically significant (all n P0.05). After treatment, the levels of serum VEGF, MMP-9 and AFP in the two groups were decreased, while the levels of serum Caspase-8 were increased, and the levels of serum VEGF, MMP-9 and AFP in the observation group were lower than those in the control group (alln P<0.05). The level of serum Caspase-8 was significantly higher than that of the control group (n P0.05), but the incidence of rash, hypertension and proteinuria in the observation group were all higher than those in the control group (alln P<0.05).n Conclusions:In the treatment of advanced liver cancer, apatinib combined with hepatic arterial chemoembolization can effectively improve the therapeutic effect and control the tumor development, but it also increases the incidence of adverse reactions, so it should be used with caution.